RxDoctor Payments Data

Angela Richmond, MD

Neurology · Kansas City, KSNPI 1144724238

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (48.8%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. It is spread thinly across 13 manufacturers, the largest accounting for just 22.1%. Reporting peaked in 2023 at $4,320 and has fallen 58.3% since, to $1,802 in 2025.

$8,399in general payments, 2019–2025

Across 59 payments — averaging $142.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Acadia Pharmaceuticals Inc$2K
  • Amneal Pharmaceuticals LLC$2K
  • AbbVie$1K
  • Boston Scientific$1K
  • Medtronic$1K
  • Abbott$255
  • plus $729 from 7 others
$76,970in research payments, 2019–2025

Across 6 payments — averaging $12,828 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Amneal Pharmaceuticals LLC$77K

What the payments were for

  • Consulting fees$4,09849%
  • Travel & lodging$1,55619%
  • Food & beverage$2,59531%
  • Education$1051%
  • Gifts$461%

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,399 in reported general payments places this provider in the 80th percentile of 131 neurology providers in Kansas.

See all neurology providers in Kansas

Medicare billing

Part B allowed, 2024
$45,764
Medicare patients
223
Services billed
518

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RytaryCarbidopa/Levodopa14$9,714
Droxidopa11$3,735
Carbidopa-LevodopaCarbidopa/Levodopa188$3,200
Rasagiline Mesylate16$2,839
Primidone57$1,812
Carbidopa-Levodopa ErCarbidopa/Levodopa43$1,591
Donepezil Hcl61$616
Propranolol Hcl35$550
Atropine Sulfate14$487
Propranolol Hcl ErPropranolol Hcl14$448
Clonazepam17$402
Memantine Hcl11$379
RivastigmineRivastigmine Tartrate11$364
Topiramate45$354
Baclofen13$337

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Amneal Pharmaceuticals LLCRytary$1,730$9,71414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 131 neurology providers in Kansas.

Other neurology in Kansas City

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →